Investment analysts at StockNews.com began coverage on shares of Tenax Therapeutics (NASDAQ:TENX – Get Free Report) in a research report issued to clients and investors on Monday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.
Tenax Therapeutics Stock Performance
NASDAQ:TENX opened at $3.99 on Monday. Tenax Therapeutics has a one year low of $2.77 and a one year high of $61.20. The firm has a 50-day simple moving average of $3.55 and a 200-day simple moving average of $3.68.
Tenax Therapeutics (NASDAQ:TENX – Get Free Report) last posted its quarterly earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($1.83) EPS for the quarter, beating the consensus estimate of ($1.99) by $0.16. On average, research analysts forecast that Tenax Therapeutics will post -6.68 earnings per share for the current year.
Tenax Therapeutics Company Profile
Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
Further Reading
- Five stocks we like better than Tenax Therapeutics
- Investing in the High PE Growth Stocks
- Don’t Overlook Campbell Soup: Here’s What Could Drive Its Stock
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Birkenstock’s Sudden Slide—Why It Might Be Your Next Big Win
- Breakout Stocks: What They Are and How to Identify Them
- Veeva’s Stock Jumps on Stellar Q2 Results—Don’t Miss Out
Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.